Baseline quantitative HBcAb strongly predicts undetectable HBV DNA and RNA in chronic hepatitis B patients treated with entecavir for 10 years

Zhang, Xi; An, Xiaocui; Shi, Lei; Yang, Xiaojiao; Chen, Yunru; Liu, Xiaojing; Li, Jianzhou; Ye, Feng; Su, Lin

doi:10.1038/s41598-021-92757-0

Cited by 2 publications

(3 citation statements)

References 26 publications

(30 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a previous study, we found that the baseline HBV DNA and HBV RNA had no prediction effect for HBV DNA and HBV RNA double-negative after long-term ETV treatment in CHB patients ( 25 ). However, the predictive value of HBV RNA levels after NA treatment remains unclear.…”

Section: Discussionmentioning

confidence: 90%

“…However, HBeAg seroconversion and HBV DNA inhibition do not reflect the clearance of HBV cccDNA in hepatocytes, and the clearance of HBV cccDNA is the aim of CHB cures. HBV RNA is the novel marker for reflecting the level of In a previous study, we found that the baseline HBV DNA and HBV RNA had no prediction effect for HBV DNA and HBV RNA double-negative after long-term ETV treatment in CHB patients (25). However, the predictive value of HBV RNA levels after NA treatment remains unclear.…”

Section: Discussionmentioning

confidence: 93%

See 1 more Smart Citation

The decline of HBV RNA associated with HBeAg seroconversion and double-negative HBV DNA and RNA in chronic hepatitis B patients who received entecavir therapy: a 10-year retrospective cohort study

Ye¹,

Zhao²,

Yang³

et al. 2022

Ann Transl Med

Self Cite

View full text Add to dashboard Cite

Background Whether the decline of hepatitis B virus (HBV) RNA was associated with antiviral efficacy in chronic hepatitis B (CHB) patients receiving long-term nucleos(t)ide analogues (NAs) therapy remains unclear. We observed the levels of serum HBV RNA in CHB patients treated with entecavir (ETV) for 10 years and explored the clinical significance of HBV RNA during long-term antiviral treatment. Methods A total of 33 hepatitis B surface antigen (HBsAg)-positive CHB patients treated with ETV for up to 10 years were recruited for this study. Liver function, HBsAg, hepatitis B envelope antigen (HBeAg), HBV DNA, and HBV RNA were measured at the baseline and each follow-up points. Antiviral efficacy was defined as negative HBV DNA (<20 IU/mL) and HBV RNA (<300 Copies/mL). Results (I) Serum HBV DNA and HBV RNA declined with the duration of antiviral treatment over 10 years (P<0.001). (II) There were positive correlations between serum HBV DNA and HBV RNA at each follow-up point (r=0.62 and P<0.001 at baseline, r=0.77 and P<0.001 at week 24, r=0.71 and P<0.001 at week 48, r=0.81 and P<0.001 at week 96, r=0.60 and P<0.01 at year 5 and r=0.77 and P<0.001 at year 10). (III) HBeAg and HBsAg levels at baseline and 10th year after ETV treatment have significant difference (P<0.05 and P<0.01). (IV) The decline of HBV RNA after ETV treatment was associated with HBeAg seroconversion, the area under the ROC curves (AUROCs) of the declines of HBV RNA were 0.25 at the baseline, 0.62 at week 24, 0.78 at week 48 and 0.86 at week 96, respectively. (V) The decline of HBV RNA after ETV treatment was associated with antiviral efficacy, the AUROCs of the declines of HBV RNA were 0.33 at the baseline, 0.74 at week 24, 0.83 at week 48 and 0.86 at week 96, respectively. Conclusions Serum HBV DNA and HBV RNA declined with the duration of antiviral treatment over 10 years. The decline of HBV RNA was associated with HBeAg seroconversion and antiviral efficacy in CHB patients receiving long-term ETV therapy, and the earliest prediction point was week 24.

show abstract

Section: Discussionmentioning

confidence: 90%

Section: Discussionmentioning

confidence: 93%

The decline of HBV RNA associated with HBeAg seroconversion and double-negative HBV DNA and RNA in chronic hepatitis B patients who received entecavir therapy: a 10-year retrospective cohort study

Ye¹,

Zhao²,

Yang³

et al. 2022

Ann Transl Med

Self Cite

View full text Add to dashboard Cite

show abstract

“…Baseline levels of anti-HBc were predictive of HBeAg seroconversion in both patients treated with PEG-IFNa and Adefovir Dipivoxil [ 95 ]. Furthermore, baseline anti-HBc levels were strong predictors of double-negative HBV-DNA and HBV-RNA in patients receiving long-term Entecavir therapy [ 100 ].…”

Section: New Tools For Treatment Monitoringmentioning

confidence: 99%

Virological Treatment Monitoring for Chronic Hepatitis B

Loggi

Gitto

Gabrielli

et al. 2022

Viruses

View full text Add to dashboard Cite

More than 250 million people worldwide are currently infected with hepatitis B, despite the effectiveness of vaccination and other preventive measures. In terms of treatment, new therapeutic approaches are rapidly developing, promising to achieve the elimination of infected cells and the complete cure of infection. The on-treatment monitoring of these innovative antiviral treatments will require the implementation of new virological tools. Therefore, new biomarkers are being evaluated besides the traditional virological and serological assays in order to obtain information on different steps of the viral replication cycle and to monitor response to therapy more accurately. The purpose of this work is to describe both standard and innovative tools for chronic hepatitis B treatment monitoring, and to analyse their potential and feasibility.

show abstract

Baseline quantitative HBcAb strongly predicts undetectable HBV DNA and RNA in chronic hepatitis B patients treated with entecavir for 10 years

Cited by 2 publications

References 26 publications

The decline of HBV RNA associated with HBeAg seroconversion and double-negative HBV DNA and RNA in chronic hepatitis B patients who received entecavir therapy: a 10-year retrospective cohort study

The decline of HBV RNA associated with HBeAg seroconversion and double-negative HBV DNA and RNA in chronic hepatitis B patients who received entecavir therapy: a 10-year retrospective cohort study

Virological Treatment Monitoring for Chronic Hepatitis B

Contact Info

Product

Resources

About